Loading company financials…
NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 0001099800
$89.90
-0.34% · delayed 15 min
$52.20B market value
What this company does
Edwards Lifesciences makes medical devices and equipment. It took in $6.07B last year, which makes it a mid-sized company. Of every dollar it sells, about 18 cents is left as profit.
Financial health
Strong finances across the board.
From Edwards Lifesciences Corp's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +11.5%
$5.44B to $6.07B
Deteriorated: -74.3%
$4.17B to $1.07B
Deteriorated: −1.4 pts
79.5% to
It makes a profit rather than burning through money.
$1.07B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$1.60B cash from operations
It holds more cash than debt, so borrowings are not a pressure.
$2.34B more cash than debt
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 11.96
It keeps less of each sale as profit than it did a year ago.
76.7% → 17.7%
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 14% a year for the next 10 years. Over the last 10 years it grew by about 12% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 18 cents of every dollar of sales as profit, earning $1.07B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.07B and generated $1.60B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from EW in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-08-28 | 2026-08-25 |
| Quarterly report(10-Q) | 2026-08-04 | 2026-06-30 |
Financial figures are from EW's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
11.96
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −59.1 pts
76.7% to 17.7%
Improved: +360.5%
$289.9M to $1.33B
Improved: -1.3%
588.6M to 580.7M
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 11% and 16%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 11.5% last year.
No — it holds more cash than debt, with $2.34B left over after paying off every borrowing. For every $1 it owes, it owns $4.08 in assets.
Expensive. Investors pay $48.6 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-23 | 2026-07-23 |
| Major event announcement(8-K) | 2026-05-08 | 2026-05-07 |
| Quarterly report(10-Q) | 2026-05-06 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-04 | 2026-05-02 |
| Major event announcement(8-K) | 2026-04-23 | 2026-04-23 |
| Shareholder voting information(DEF 14A) | 2026-03-26 | 2026-05-07 |
| Annual report(10-K) | 2026-02-25 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-10 | 2026-02-10 |
| Major event announcement(8-K) | 2026-01-12 | 2026-01-09 |
| Quarterly report(10-Q) | 2025-11-05 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Major event announcement(8-K) | 2025-08-19 | 2025-08-19 |
| Quarterly report(10-Q) | 2025-08-06 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-06 | 2025-08-06 |
| Major event announcement(8-K) | 2025-07-25 | 2025-07-21 |
| Major event announcement(8-K) | 2025-07-24 | 2025-07-24 |
| Major event announcement(8-K) | 2025-05-08 | 2025-05-08 |
Coverage from the last 30 days
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
Yahoo Finance ·
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
Yahoo Finance ·
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
Yahoo Finance ·
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
Yahoo Finance ·
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care
Yahoo Finance ·
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Yahoo Finance ·
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
Yahoo Finance ·
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Yahoo Finance ·
Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom
Yahoo Finance ·
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
Yahoo Finance ·
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Yahoo Finance ·
Primary sources and further research